PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 6 of 39 · 913 questions tagged clinical-trials.

913 questions · sorted by votes · page 6 of 39

33 votes 3 answers13k views
SELECT reported HR 0.80 for MACE. What does that actually license me to conclude?

I keep seeing SELECT summarised as "semaglutide cuts heart attacks and strokes by 20%". I understand that 20% comes from the hazard ratio of 0.80, and I understand…

semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
asked by sinead_gaffney 14k · 23 months ago
32 votes 5 answers59k views
Is there any published stability data for mazdutide at minus 20 °C?

Details up front: mazdutide · minus 20 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

646 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
asked by vial_five 15k · 23 months ago
32 votes 5 answers52k views
Does the FLOW population resemble anyone asking about dulaglutide here?

What I have: FLOW · dulaglutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by tyndall_haze 48k · 22 months ago
32 votes5 answers45k views
How comparable are oral semaglutide and liraglutide on the evidence available?

For reference: oral semaglutide · liraglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by tare_weight 47k · 16 months ago
32 votes 5 answers43k views
What did the placebo arm of SURMOUNT-2 report for hair thinning?

What I have: SURMOUNT-2 · hair thinning. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by esben_lykke 15k · 22 months ago
32 votes0 answers39k views
What does ATTAIN-1 tell me about early satiety at the 50 mg dose?

Details up front: ATTAIN-1 · early satiety · 50 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by aine_mulcahy 35k · 23 months ago
32 votes5 answers35k views
What is the reported incidence of early satiety on tirzepatide in SURMOUNT-4?

The case in front of me: early satiety · tirzepatide · SURMOUNT-4. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by tadhg_o_riordan 14k · 14 months ago
32 votes 2 answers35k views
What does ESSENCE tell me about constipation at the 15 mg dose?

Details up front: ESSENCE · constipation · 15 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by vial_five 15k · 2.3 years ago
32 votes 5 answers35k views
What does the mechanism of tirzepatide predict that SOUL did not test?

The particulars: tirzepatide · SOUL. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to reason…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

83 questions
asked by rania_haddad 17k · 2.0 years ago
32 votes 2 answers34k views
Is 30 mg weekly a defensible maintenance dose for retatrutide?

What I have: 30 mg · retatrutide. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work matters.…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

44 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
asked by claudia_ferrante 46k · 14 months ago
32 votes5 answers31k views
What is a treatment-policy estimand and why does it change the number?

I am reading the trial table rather than the press release, which is why the numbers differ. I can predict the outcome but I cannot explain it, which means I will get…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
sterile-water
sterile-water

Preservative-free sterile water for injection: appropriate for a single-withdrawal presentation, a poor choice for anything you intend to open…

14 questions
asked by k_szabo 45k · 12 months ago
32 votes0 answers26k views
What does SURMOUNT-2 tell me about nausea at the 15 mg dose?

Numbers first: SURMOUNT-2 · nausea · 15 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by j_wierzbicki 45k · 22 months ago
32 votes 5 answers24k views
How comparable are retatrutide and cagrilintide on the evidence available?

Stated plainly: retatrutide · cagrilintide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by wren_calloway 14k · 15 months ago
32 votes0 answers14k views
What does REDEFINE-1 actually establish about semaglutide?

For reference: REDEFINE-1 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
renal-outcomes
renal-outcomes

Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.

14 questions
asked by j_wierzbicki 45k · 11 months ago
32 votes0 answers12k views
What did the placebo arm of STEP 2 report for nausea?

For reference: STEP 2 · nausea. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by sasha_ferreira 15k · 12 months ago
32 votes0 answers11k views
What does STEP 8 report at the 10 mg dose level?

Numbers first: STEP 8 · 10 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
subcutaneous
subcutaneous

Subcutaneous administration as a route: absorption kinetics from abdomen versus thigh versus upper arm, tissue depth, and why site rotation…

14 questions
asked by oona_kekkonen 16k · 19 months ago
32 votes 5 answers9.8k views
Does the SURMOUNT-3 population resemble anyone asking about dulaglutide here?

Details up front: SURMOUNT-3 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by eoin_mcgarry 16k · 11 months ago
31 votes 5 answers35k views
Does the TRIUMPH-3 population resemble anyone asking about tirzepatide here?

The case in front of me: TRIUMPH-3 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by dead_volume 49k · 12 months ago
31 votes 5 answers31k views
What does PIONEER-4 actually establish about tirzepatide?

Concretely: PIONEER-4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by wren_calloway 14k · 13 months ago
31 votes 4 answers30k views
What does SUSTAIN-6 tell me about reflux at the 10 mg dose?

Setup, so nobody has to ask: SUSTAIN-6 · reflux · 10 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by ines_brandt 93k · 2.1 years ago
31 votes 4 answers29k views
What does the mechanism of semaglutide predict that SURPASS-3 did not test?

Conditions: semaglutide · SURPASS-3. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically, because it…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

83 questions
asked by seamus_brady 17k · 11 months ago
31 votes5 answers25k views
What did the placebo arm of SURMOUNT-2 report for reflux?

Stated plainly: SURMOUNT-2 · reflux. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
asked by area_percent 13k · 2.1 years ago
31 votes 5 answers22k views
What does ESSENCE report at the 2 mg dose level?

Concretely: ESSENCE · 2 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I have…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
asked by Dr_Fatima_Belkacem 52k · 13 months ago
31 votes 5 answers19k views
What does SURMOUNT-1 tell me about headache at the 50 mg dose?

What I have: SURMOUNT-1 · headache · 50 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

14 questions
asked by tess_amankwah 48k · 14 months ago